Celgene International Sárl Release: Clinical Data Evaluating Oral REVLIMID(R) Either with Rituximab or Following Rituximab Combination for Patients with Chronic Lymphocytic Leukemia (CLL) Presented at American Society of Hematology

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) announced that clinical data from two investigational studies evaluating the use of REVLIMID® (lenalidomide) either with rituximab or following a rituximab-containing regimen in patients with chronic lymphocytic leukaemia (CLL) were presented at the 52nd American Society of Hematology annual meeting.